AU2002366715A1 - Ph-sensitive polymeric conjugates of an anthracycline drug - Google Patents

Ph-sensitive polymeric conjugates of an anthracycline drug

Info

Publication number
AU2002366715A1
AU2002366715A1 AU2002366715A AU2002366715A AU2002366715A1 AU 2002366715 A1 AU2002366715 A1 AU 2002366715A1 AU 2002366715 A AU2002366715 A AU 2002366715A AU 2002366715 A AU2002366715 A AU 2002366715A AU 2002366715 A1 AU2002366715 A1 AU 2002366715A1
Authority
AU
Australia
Prior art keywords
amino acids
units
amino
oligopeptides
methacryloylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366715A
Other languages
English (en)
Other versions
AU2002366715A8 (en
Inventor
Tomas Etrych
Marketa Jelinkova
Marek Kovar
Blanka Rihova
Karel Ulbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Leciva AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leciva AS filed Critical Leciva AS
Publication of AU2002366715A1 publication Critical patent/AU2002366715A1/en
Publication of AU2002366715A8 publication Critical patent/AU2002366715A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002366715A 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug Abandoned AU2002366715A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
CZPV4653-01 2001-12-20
PCT/CZ2002/000070 WO2003053473A2 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug

Publications (2)

Publication Number Publication Date
AU2002366715A1 true AU2002366715A1 (en) 2003-07-09
AU2002366715A8 AU2002366715A8 (en) 2003-07-09

Family

ID=5473644

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002366715A Abandoned AU2002366715A1 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug

Country Status (18)

Country Link
US (1) US7919076B2 (OSRAM)
EP (2) EP1782833A3 (OSRAM)
JP (1) JP4718117B2 (OSRAM)
KR (1) KR20040076874A (OSRAM)
AT (1) ATE439864T1 (OSRAM)
AU (1) AU2002366715A1 (OSRAM)
CA (1) CA2470976A1 (OSRAM)
CZ (1) CZ293787B6 (OSRAM)
DE (1) DE60233434D1 (OSRAM)
DK (1) DK1463529T5 (OSRAM)
EA (1) EA007353B1 (OSRAM)
ES (1) ES2331303T3 (OSRAM)
HU (1) HUP0500541A3 (OSRAM)
PL (1) PL216518B1 (OSRAM)
PT (1) PT1463529E (OSRAM)
SI (1) SI1463529T1 (OSRAM)
SK (1) SK2912004A3 (OSRAM)
WO (1) WO2003053473A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294996B6 (cs) * 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
CA2583700A1 (en) 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
CZ2005558A3 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
EP2799868A3 (en) 2006-08-09 2015-04-22 Sumitomo Bakelite Co., Ltd. Sugar chain-capturing substance and use thereof
CZ2006505A3 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
CZ298945B6 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
US7790765B2 (en) 2007-04-30 2010-09-07 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
CZ301288B6 (cs) * 2008-10-23 2009-12-30 Zentiva, A. S Polymerní prípravek se synergickým úcinkem pri lécbe nádorových onemocnení
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
EP3525808A4 (en) * 2016-10-14 2020-06-24 University of Utah Research Foundation ANTIBODY-POLYMER-DRUG CONJUGATES
WO2020214858A1 (en) * 2019-04-17 2020-10-22 Avidea Technologies, Inc. Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
CZ309828B6 (cs) * 2019-10-09 2023-11-15 I.T.A.-Intertact S.R.O. Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití
EP4051320A1 (en) * 2019-10-30 2022-09-07 CIS Pharma AG Biocompatible polymeric drug carriers for delivering active agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs

Also Published As

Publication number Publication date
CZ293787B6 (cs) 2004-07-14
DK1463529T5 (da) 2011-06-27
WO2003053473A3 (en) 2004-04-29
DE60233434D1 (de) 2009-10-01
HUP0500541A2 (hu) 2005-09-28
PT1463529E (pt) 2009-11-03
ATE439864T1 (de) 2009-09-15
ES2331303T3 (es) 2009-12-29
WO2003053473A2 (en) 2003-07-03
ES2331303T9 (es) 2011-08-18
CA2470976A1 (en) 2003-07-03
US7919076B2 (en) 2011-04-05
EP1463529A2 (en) 2004-10-06
EA200400802A1 (ru) 2005-02-24
CZ20014653A3 (cs) 2003-08-13
PL216518B1 (pl) 2014-04-30
EP1463529B9 (en) 2011-03-23
JP4718117B2 (ja) 2011-07-06
US20060057099A1 (en) 2006-03-16
EP1782833A3 (en) 2008-03-19
SI1463529T1 (sl) 2010-01-29
JP2005519044A (ja) 2005-06-30
PL370719A1 (en) 2005-05-30
HUP0500541A3 (en) 2011-08-29
EP1463529B1 (en) 2009-08-19
AU2002366715A8 (en) 2003-07-09
SK2912004A3 (en) 2004-12-01
EP1782833A2 (en) 2007-05-09
KR20040076874A (ko) 2004-09-03
DK1463529T3 (da) 2009-10-19
EA007353B1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
AU2002366715A8 (en) Ph-sensitive polymeric conjugates of an anthracycline drug
RU2018126304A (ru) Конъюгированные иммуноглобулины с c-концевым лизином
TR200200252T2 (tr) Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
JP2019502684A5 (OSRAM)
CO5550468A2 (es) Inmunoconjugados del anticuerpo cd44 citotoxico
ATE399177T1 (de) Derivate therapeutischer peptide
Yasutake et al. Reactivity of human leukocyte elastase and porcine pancreatic elastase toward peptide-4-nitroanilides containing model desmosine residues. Evidence that human leukocyte elastase is selective for crosslinked regions of elastin
ATE437647T1 (de) Transporter mit beabstandeten arginin-teilchen
JPH11505554A (ja) キノン類を用いて配位子の光化学的固定方法
DE69327229D1 (de) Multivalente einkettige Antikörper
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
DK0388914T3 (da) Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse
Kawasaki et al. Amino acids and peptides. XIV. Laminin related peptides and their inhibitory effect on experimental metastasis formation
DE68927379D1 (de) Plättchen blockierende peptide
DK1179537T3 (da) Fastfasepeptidsyntesefremgangsmåde
JP2005519044A5 (OSRAM)
ATE118686T1 (de) Biologisch wirksame polymere arzneistoffderivate.
ATE238348T1 (de) Aus thymischen hormonen abstammende peptid konjugierte, deren verwendung als medikamente und aus deren enthaltende zusammensetzungen
DE4402756A1 (de) Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
Birr et al. Molecular perspectives of synthetic mast cell-degranulating peptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase